Login
Recent Posts
- Alzheimer’s blood test gets FDA breakthrough device designation March 14, 2024
- AR1001 Phase 3 trial in early Alzheimer’s to begin recruiting in UK March 7, 2024
- AVP-786 fails to ease Alzheimer’s-related agitation in Phase 3 trial February 29, 2024
- Clinical hold lifted for Phase 2 trial of XPro1595 in mild Alzheimer’s February 22, 2024
- Rexulti approved in Canada for agitation in Alzheimer’s dementia February 15, 2024